PDCD1 and pneumonitis: We found ICI monotherapy was linked to a higher risk of grade 3-5 immune‐related pneumonitis compared to nab-PTX+ICI, and comparing with PD-1, PD-1+PTX was associated with a statistically significant lower risk of grade 1-5 pneumonitis.